课题基金 / 基金详情

Prostate Oncology

Prostate Oncology
前列腺肿瘤学
批准号:
8300276
负责人:
MAX S. WICHA
金额:
$36.67万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-01 至 2017-05-31
关键词:
AgeAgingApoptoticAreaBiological MarkersBiologyCancer CenterCancer Center Support GrantCancer FamilyCancer PatientCancer Therapy Evaluation ProgramCandidate Disease GeneCaringCastrationCell LineChromosome MappingClinicClinicalClinical ResearchClinical TrialsCollaborationsCommitCorrelative StudyDNADNA MethyltransferaseDNA Modification MethylasesDNA Tumor VirusesDataDepartment of DefenseDetectionDevelopmentDiagnosisDiseaseDisease ProgressionE2F1 geneEZH2 geneEarly DiagnosisEnvironmentEpidemiologyEpigenetic ProcessEpithelialEtiologyEventFamilyFundingGene ExpressionGenesGeneticGenetic TranscriptionGenotypeGoalsGrantGrowthHistone DeacetylaseHumanIL6 geneIndividualInfectionInheritedIntegrinsInterleukin-6InvestigationLaboratoriesLigandsLinkMalignant - descriptorMalignant Bone NeoplasmMalignant NeoplasmsMalignant neoplasm of prostateMedicalMedical OncologistMetalloproteasesMetastatic Neoplasm to the BoneMissionMolecularMorbidity - disease rateNational Institute of Diabetes and Digestive and Kidney DiseasesNeoplasm MetastasisOncogenesOutcomePathway interactionsPatientsPolyomavirusPredispositionPreventionProstateProstate Cancer therapyProstatic NeoplasmsProteinsProteomicsPublicationsPublishingQuality of lifeRadiation OncologyRadiosurgeryResearchResearch PersonnelResearch SupportResearch TrainingResistanceResourcesRobin birdRoleSamplingScanningSchoolsScientistSeedsSeminalSerumSiteSolutionsSouthwest Oncology GroupStructure of base of prostateSurveysSystemTechnologyTestingTherapeutic InterventionTherapy Clinical TrialsTrainingTransformed Cell LineTranslatingTranslational ResearchTreatment-Related CancerTumor Suppressor GenesUnited States National Institutes of HealthUniversity of Michigan Comprehensive Cancer CenterUrologic CancerUrologic OncologyUrologistUrologyVascular Endothelial Growth Factor Receptor-2VorinostatWood materialangiogenesisbasebonecancer geneticsclinical practiceclinically relevantcohortdisease diagnosisearly onsetexomegenetic analysisgenome wide association studygenome-wide linkageimprovedinhibitor/antagonistmeetingsmembermenmortalitymultidisciplinarynew technologynoveloncologyoncology programoutcome forecastprogramsprospectiveprostate cancer preventionreceptorstandard of caresurvivorshiptherapy developmenttooltumortumor growthtumor progression

项目摘要

项目成果

MAX S. WICHA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Prostate Oncology Program is an interdisciplinary group of 34 laboratory, translational and clinical researchers from 11 departments and four schools with over $13 million in annual direct research support including nearly $4 million from the NCI. The Prostate Oncology Program, formerly the Urologic Oncology Program, was renamed during this grant period to reflect Its primary mission and critical mass of strength In translating basic and clinical discoveries in prostate cancer into effective medical solutions. The program includes a Prostate SPORE (recently renewed), a PO1 on the Biology of Prostate Cancer Bone Metastasis (recently renewed), a recently renewed Department of Defense funded Prostate Cancer Clinical trials Consortium site (DOD-PCCTC), a prostate-focused Early Disease Research Network (EDRN) site (new this period) and a NIDDK training grant In Clinical and Translational Research Training in Urology (T32). Over this grant period the 34 program members published 563 publications of which 27,9% are intraprogrammatic and 31.3% are Inter-programmatic collaborations. The Program is committed to creating and sustaining a multidisciplinary environment for basic and clinical researchers studying prostate cancer. The scientific aims of the Prostate Oncology Programs are 1) to investigate the genetic and epigenetic events that contribute to malignant transformation in prostate cancer, 2) to characterize aberrations in the tumor microenvironment that facilitate the growth or metastasis of prostate cancer, 3) to translate basic scientific discoveries to develop new biomarkers and therapies in urologic cancers, and 4) to evaluate clinical outcomes with the purpose of guiding therapy development while reducing cancer-related mortality as well as cancer and therapy-associated morbidity. Among the most high Impact research conducted during this grant period were the seminal findings related to the discovery of TMPRSS-ETS fusions in prostate cancer by program members. The objective of the Prostate Oncology Program Is to understand the biology of prostate cancer and to use this information to develop new tools for the detection, diagnosis, prevention, and treatment of prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting breast cancer stem cells
Targeting breast cancer stem cells
Targeting breast cancer stem cells
Cancer Cell Biology
海外基金